Project 4: FTO Inhibition to Enhance the Therapeutic Index of Radiotherapy

项目4：FTO抑制提高放疗治疗指数

• 批准号: 10707907
• 负责人: Erinn B. Rankin
• 金额: $ 37.18万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-21 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10707907
• 关键词: Acute; Adult; Apoptosis; Biological Assay; Bone Marrow; Cancer Cell Growth; Cell Survival; Cells; Cervical; Cervix Neoplasms; Collaborations; Complement; DNA Repair; Data; Failure; Genetic; Glutamine; Glutathione; Goals; Growth; Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Human; In Vitro; Intestines; Kidney; Late Effects; Lung; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Maps; Metabolic; Metabolic Pathway; Metabolism; Mission; Mitochondria; Modeling; Modification; Molecular; Molecular Target; Morbidity - disease rate; Mus; Non-Small-Cell Lung Carcinoma; Normal tissue morphology; Oncogenic; Oral mucous membrane structure; Oxidative Stress; Pathway interactions; Patients; Public Health; RNA; Radiation; Radiation Dose Unit; Radiation Tolerance; Radiation therapy; Radiation-Sensitizing Agents; Radiobiology; Radiosensitization; Renal carcinoma; Research; Role; Safety; Salivary Glands; Signal Transduction; Solid Neoplasm; Supplementation; Testing; Therapeutic; Therapeutic Index; Toxic effect; Treatment Failure; Tumor Tissue; United States National Institutes of Health; alpha ketoglutarate; analytical tool; antitumor effect; biological adaptation to stress; cancer cell; effective therapy; epitranscriptomics; fat mass and obesity-associated protein; gain of function; improved; in vivo; innovation; insight; knock-down; lung cancer cell; metabolomics; mortality; multidisciplinary; mutant; novel; nucleotide metabolism; overexpression; oxidative damage; pharmacologic; pre-clinical; radiation response; response; small molecule; stable isotope; standard care; targeted cancer therapy; therapeutic target; therapy outcome; therapy resistant; transcriptome sequencing; tumor; tumor growth; tumor xenograft; uptake

Abstract (Project 4) Radiation therapy is a standard treatment for many solid tumors including cervical, non-small cell lung (NSCLC) cancer, and head and neck cancer. While effective in a large proportion of patients, local failure remains a significant cause of patient morbidity and mortality. An attractive strategy to radiosensitize tumors is targeting cancer-specific glutamine metabolic reprogramming as this pathway supports tumor growth, survival, oxidative stress responses and DNA damage repair. The RNA demethylase FTO is emerging as a therapeutic target for cancer therapy as it is overexpressed and oncogenic in several cancers including cervical, non-small cell lung cancer (NSCLC), and head and neck cancers. However, FTO has not previously been explored as a target for tumor radiosensitization. Preliminary studies demonstrate that FTO inhibition reduces tumor growth and survival in vitro and in vivo. At the molecular level, FTO inhibition reduces SLC1A5 expression and glutamine uptake in cancer cells. Importantly, FTO inhibition radiosensitizes cervical and KEAP1 mutant NSCLC cancer cells. This proposal will test the hypothesis that inhibition the RNA demethylase fat-mass and obesity-associated (FTO) will enhance the therapeutic index of radiotherapy in solid tumors through the inhibition of glutamine metabolism. Aim 1 will determine the anti-tumor effects of FTO inhibition in combination with radiation on a range of solid tumors cancers using genetic and pharmacologic approaches. Aim 2 determine if FTO inhibition enhances the radiation response in cancer cells by reducing glutamine metabolism, oxidative stress and/or DNA damage repair responses using knockdown and gain of function approaches. Aim 3 will test the hypothesis that FTO inhibition will not impact the radiation sensitivity of normal tissues that develop radiation- induced toxicity when treating cervical, NSCLC and HNSCC tumors. The acute and late effects of FTO inhibition on the radiation response in the bone marrow, intestine (collaboration with Project 1), salivary gland and oral mucosa (collaboration with Project 2), and lung (collaboration with Project 3) will be analyzed using models of global conditional FTO inactivation in adult mice. Together with Projects 1, 2 and 3 this project will investigate the role of FTO in both the tumor and normal tissue radiation response with the goal of ascertaining the therapeutic potential of FTO-based radiosensitizers. In addition to determining the tumor types that can be effectively and safely treated with FTO inhibition, they will use cutting edge analytical tools to study the mechanism of action. Successful completion of these aims will 1) identify FTO is an epitranscriptomic regulator of cancer cell glutamine metabolism and oxidative stress; 2) provide the preclinical data to support FTO as a safe and effective molecular target to radiosensitize tumors; 3) provide proof of concept studies to demonstrate that small molecule targeting of FTO demethylase activity can radiosensitize tumors.

摘要(项目4) 放射治疗是许多实体肿瘤的标准治疗方法，包括宫颈、非小细胞肺癌(NSCLC)。 癌症，还有头颈癌。虽然在很大一部分患者中有效，但局部衰竭仍然是一种 患者发病率和死亡率的重要原因。肿瘤放射增敏的一个有吸引力的策略是靶向 癌症特异性谷氨酰胺代谢重编程，因为这一途径支持肿瘤的生长、存活、氧化 应激反应和DNA损伤修复。RNA去甲基酶FTO正在成为治疗的靶点 在几种癌症中过度表达和致癌的癌症治疗，包括宫颈癌、非小细胞肺癌 癌症(非小细胞肺癌)和头颈部癌症。然而，FTO以前并未被探索为 肿瘤放射增敏。初步研究表明，FTO抑制可降低肿瘤生长和存活率 在体外和体内。在分子水平上，FTO抑制减少了SLC1A5的表达和谷氨酰胺摄取 癌细胞。重要的是，FTO抑制使宫颈癌细胞和Keap1突变的NSCLC癌细胞变得敏感。这 该提案将检验抑制RNA去甲基酶与脂肪质量和肥胖相关的假设 (FTO)将通过抑制实体瘤的放射治疗而提高放射治疗指数 谷氨酰胺代谢。目的1确定FTO抑制与联合应用的抗肿瘤作用 使用遗传学和药理学方法对一系列实体肿瘤癌症进行放射治疗。目标2确定是否 FTO抑制通过降低谷氨酰胺代谢，氧化，增强癌细胞的辐射反应 应激和/或DNA损伤修复反应使用击倒和获得功能的方法。AIM 3将测试 假设FTO抑制不会影响产生辐射的正常组织的辐射敏感性- 治疗宫颈、NSCLC和HNSCC肿瘤时的毒性反应。FTO抑制的急性和远期效应 骨髓、肠(与项目1合作)、唾液腺和口腔的辐射反应 将使用以下模型分析粘膜(与项目2协作)和肺(与项目3协作) 成年小鼠的全局条件FTO失活。与项目1、2和3一起，该项目将调查 FTO在肿瘤和正常组织放射反应中的作用 FTO类放射增敏剂的治疗潜力。除了确定肿瘤类型之外， 有效和安全地治疗FTO抑制，他们将使用尖端分析工具来研究 作用机制。这些目标的成功完成将1)确定FTO是一个外在的调节器 对癌细胞谷氨酰胺代谢和氧化应激的影响；2)提供临床前数据支持FTO作为一种 安全有效的肿瘤放射增敏分子靶点；3)提供概念性研究的证据 靶向FTO脱甲基酶活性的小分子可使肿瘤放射增敏。